Revisiting biomarker discovery by plasma proteomics.
Revisiting biomarker discovery by plasma proteomics.
复制标题
DOI：
10.15252/msb.20156297
复制
发表时间：
2017-09-26
影响因子：
9.9
通讯作者：
Mann M
中科院分区：
文献类型：
--
作者：
Geyer PE;Holdt LM;Teupser D;Mann M
血液的临床分析是医学中最广泛的诊断程序，血液生物标志物用于对患者进行分类并支持治疗决策。然而，现有的生物标志物远远不够全面，往往缺乏特异性，新的生物标志物的开发速度非常缓慢。如本文所述，基于质谱（MS）的蛋白质组学已成为生物学研究中的一项强大技术，现在正准备对血浆蛋白质组进行深入的表征。以前的“三角策略”旨在在小的队列中发现单一生物标志物候选物，然后在更大的验证队列中进行经典的免疫测定。我们提出了一个“矩形”血浆蛋白质组分析策略，其中大队列的蛋白质组模式与其健康和疾病的表型相关。将这些概念转化为临床实践将需要重新构建诊断决策的几个方面，我们讨论了这个方向的一些初步步骤。
Clinical analysis of blood is the most widespread diagnostic procedure in medicine, and blood biomarkers are used to categorize patients and to support treatment decisions. However, existing biomarkers are far from comprehensive and often lack specificity and new ones are being developed at a very slow rate. As described in this review, mass spectrometry (MS)‐based proteomics has become a powerful technology in biological research and it is now poised to allow the characterization of the plasma proteome in great depth. Previous “triangular strategies” aimed at discovering single biomarker candidates in small cohorts, followed by classical immunoassays in much larger validation cohorts. We propose a “rectangular” plasma proteome profiling strategy, in which the proteome patterns of large cohorts are correlated with their phenotypes in health and disease. Translating such concepts into clinical practice will require restructuring several aspects of diagnostic decision‐making, and we discuss some first steps in this direction.